We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current IPSC market cap is 94.38M. The company's latest EPS is USD -1.6074 and P/E is -0.68.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 148k | 268k | 855k | 770k | 791k |
| Operating Income | -39.85M | -27.4M | -31.31M | -34.76M | -34.79M |
| Net Income | -32.72M | -39.4M | -28.06M | -31.21M | -31.22M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 5.2M | 2.24M |
| Operating Income | -239.68M | -53.9M | -94.88M | -133.83M | -130.18M |
| Net Income | -238.77M | -53.58M | -95.82M | -130.93M | -136.67M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 397.55M | 360.69M | 348.51M | 416.45M | 388.62M |
| Total Liabilities | 178.32M | 175.94M | 170.62M | 194.34M | 192.93M |
| Total Equity | 219.23M | 184.75M | 177.88M | 222.1M | 195.69M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 90.9M | 106.78M | 437.38M | 486.54M | 360.69M |
| Total Liabilities | 2.99M | 33.43M | 41.14M | 183.81M | 175.94M |
| Total Equity | -91.86M | -106.41M | 396.24M | 302.74M | 184.75M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -62.12M | -88.35M | -30.25M | -57.58M | -85.89M |
| Investing | 42.53M | 61.13M | 11.54M | -22.32M | 16.88M |
| Financing | -9.37M | -9.73M | 18.2M | 74.89M | 75.17M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -11.77M | -41.27M | -89M | 14.05M | -88.35M |
| Investing | -19.01M | -22.76M | -298.34M | -13.13M | 61.13M |
| Financing | 74.84M | 47.69M | 417.77M | 27.16M | -9.73M |
| Market Cap | 94.38M |
| Price to Earnings Ratio | -0.68 |
| Price to Sales Ratio | 41.44 |
| Price to Cash Ratio | 1.96 |
| Price to Book Ratio | 0.5 |
| Dividend Yield | - |
| Shares Outstanding | 85.03M |
| Average Volume (1 week) | 874.61k |
| Average Volume (1 Month) | 839.08k |
| 52 Week Change | -53.36% |
| 52 Week High | 5.51 |
| 52 Week Low | 0.98 |
| Spread (Intraday) | 1.99 (66.33%) |
| Company Name | Century Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.centurytx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
